|本期目录/Table of Contents|

[1]郭小燕,冯玉宝,许艳梅,等.血栓弹力图评价替格瑞洛和氯吡格雷在急性ST段抬高型心肌梗死中抗血小板的疗效[J].国际心血管病杂志,2016,05:307-310.
　GUO Xiaoyan,FENG Yubao,XU Yanmei,et al.Evaluation of the antiplatelet effects of ticagrelor and clopidogrel in acute ST segment elevation myocardial infarction by thrombelastogram[J].International Journal of Cardiovascular Disease,2016,05:307-310.
点击复制

血栓弹力图评价替格瑞洛和氯吡格雷在急性ST段抬高型心肌梗死中抗血小板的疗效(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年05期
页码:
307-310
栏目:
临床研究
出版日期:
2016-09-20

文章信息/Info

Title:
Evaluation of the antiplatelet effects of ticagrelor and clopidogrel in acute ST segment elevation myocardial infarction by thrombelastogram
作者:
郭小燕; 冯玉宝; 许艳梅; 李永玲; 苏平
017000 内蒙古医科大学鄂尔多斯临床医学院鄂尔多斯市中心医院心内科
Author(s):
GUO Xiaoyan;  FENG Yubao;  XU Yanmei;  LI Yongling;  SU Ping.
Department of Cardiology, Ordos Central Hospital, Ordos School of Clinical Medicine, Inner Mongolia Medical University, Inner Mongolia 017000, China
关键词:
血栓弹力图; 急性ST段抬高型心肌梗死; 替格瑞洛; 氯吡格雷
Keywords:
Thrombelastogram;  Acute ST segment elevation myocardial infarction;  Ticagrelor;  Clopidogrel
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.05.014
文献标识码:
-
摘要:
目的:通过血栓弹力图评价替格瑞洛和氯吡格雷在急性ST段抬高型心肌梗死(STEMI)中抗血小板的疗效。方法:60例STEMI患者分为两组,阿司匹林+氯吡格雷组(Ⅰ组,n=30)和阿司匹林+替格瑞洛组(Ⅱ组,n=30),于抗血小板药物负荷剂量给药2h后和维持治疗3个月后,使用血栓弹力图检测花生四烯酸(AA)途径和二磷酸腺苷(ADP)受体途径诱导的血小板抑制率。结果:抗血小板药物负荷剂量给药2h后和维持治疗3个月后,Ⅱ组ADP受体途径诱导的血小板抑制率均明显高于Ⅰ组[(54.67&#
Abstract:
Objective:To evaluate the antiplatelet effects of ticagrelor and clopidogrel in acute ST segment elevation myocardial infarction(STEMI)by thrombelastogram.Methods:60 STEMI patients were divided into two groups: aspirin+clopidogrel group(group I, n=

参考文献/References

[1] Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Eur Heart J, 2012, 33(20): 2569 -2619.
[2] 邢 元,李为民. 氯吡格雷抵抗中基因多态性研究进展[J]. 国际心血管病杂志,2014,41(2):91-94.
[3] 任晓楠,王明生,赵 霞,等.替格瑞洛与氯吡格雷在行冠状动脉介入治疗的不稳定型心绞痛患者中血小板功能抑制及临床疗效和安全性的研究[J]. 中华临床医师杂志,2015,9(17):3294-3297.
[4] Vlachojannis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel resistance: current aspects and future direction[J]. Hellenic J Cardiol, 2011, 52(3):236-245.
[5] 陈 韬,朱 荔,赵仙先,等. 氯吡格雷抵抗的实验室诊断及临床价值[J]. 国际心血管病杂志,2015,42(4):225-228.
[6] 朱永红,贾国良,周 秒,等.替格瑞洛治疗41例急性冠脉综合症患者的临床疗效[J].中国介入心脏病学杂志,2013,21(6):374-376.
[7] 刘位欣,陈永旭,常 康.血栓弹力图评价急性冠脉综合征患者抗血小板治疗效果的临床研究[J].中国临床医生,2014,42(9):106-108.
[8] Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO(Platelet Inhibition and Patient Outcomes)PLATELET substudy[J]. J Am Coll Cardiol,2010,56(18): 1456-1462.
[9] 马颖艳,王艳霞,徐白鸽,等.替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究[J].中国介入心脏病学杂志,2014,22(6): 380-383.
[10] Yao J, Zhao L, Zhao Q, et al.NF-κB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis [J]. Cell Death Dis,2014,(5):1283.
[11] Vrijens B, Claeys MJ, Legrand V, et al. Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data(the TWICE project)[J]. Br J Clin Pharmacol, 2014, 77(5):746-755.
[12] Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies [J]. Am Heart J,2011,162(1):160-165.
[13] Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies[J]. Circ Cardiovasc Genet,2010, 3(6):556-566.
[14] Howard BM, Kornblith LZ, Redick BJ. et al. The effects of alcohol on coagulation in trauma patients: interpreting thrombelastography with caution[J]. J Trauma Acute Care Surg, 2014, 77(6):865-871.
[15] O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2013, 127(4): 362-425.
[16] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. J Am Coll Cardiol, 2011, 58(24): 44-122.
[17] Gurbel PA, Kevin P, Kathleen B, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study[J]. Circulation, 2010, 121(10):1188-1199.
[18] Serebruany VL, Tomek A, Pokov AN, et al. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner [J].Expert Rev Cardiovasc Ther, 2015,13(12):1333-1344.
[19] Andell P, James SK, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: An analysis from the Platelet Inhibition and Patient Outcomes(PLATO)Trial [J]. J Am Heart Assoc, 2015, 4(10): e002490.
[20] Hagström E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study [J]. Eur Heart J, 2016, 37(16):1325-1333.
[21] Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines [J]. J Am Coll Cardiol, 2013, 61(23):e179-347.
[22] 马 莉,程国杰,郭丽敏,等. 应用血栓弹力图评价糖尿病对急性冠状动脉综合征患者血小板抑制率的影响[J].中国心血管病杂志,2013,18(6):105-107.
[23] 李丹丹,任艺虹,杨庭树.血栓弹力图法与比浊法在冠心病患者血小板功能检测中的比较[J]. 中国循环杂志,2013, 28(4):318-320.
[24] Hamsten A. The hemostatic system and coronary heart disease [J]. Thromb Res, 1993, 70(1):1-38.

备注/Memo

备注/Memo:
通信作者:冯玉宝, Email:xnkfyb@sina.com
更新日期/Last Update: 2016-09-20